Subject: ORN abstract

From: wade rinehart <waderpt@gmail.com>

Date: 9/14/2015 1:46 PM **To:** info@hyperbaricce.com

Hyperbaric oxygen therapy and mandibular osteoradionecrosis: a retrospective study and analysis of treatment outcomes.

David LA¹, Sàndor GK, Evans AW, Brown DH.

Author information

Abstract

BACKGROUND: Hyperbaric oxygen (HBO) therapy is recognized as an adjunctive treatment for osteoradionecrosis (ORN). It may also be used prophylactically in patients who require dental extractions and are at high risk for developing ORN. This article reviews the treatment outcomes of patients treated with HBO therapy at the Toronto General Hospital from 1985 to 1997.

MATERIALS AND METHODS: A total of 297 charts of patients treated with HBO were reviewed. Criteria assessed included age of patient, gender, original diagnosis, radiation dose, time between radiation treatment and onset of ORN, presence or absence of fracture, orocutaneous fistula, pain, history of a precipitating event triggering ORN, medical status, HBO therapy (total oxygen time, number of dives), method of treatment of ORN and follow-up period. Minimum patient follow-up time for inclusion in the study was 6 months.

RESULTS: Adequate information to meet the inclusion criteria was obtained for 75 patients. Group A (51 patients) had been treated for overt ORN with HBO alone, HBO with sequestrectomy, or HBO with sequestrectomy and reconstruction. Group B (24 patients at risk for developing ORN) had been treated with HBO prophylactically for dental extractions. In group A, only 3 patients (5.9%) failed to show improvement. In group B, only one patient (4.2%) had complications during healing.

CONCLUSIONS: Encouraging results were achieved when HBO was used in the 2 groups described above. This paper supports existing literature on the potential benefit of HBO as a prophylactic agent and adjunctive treatment of ORN.

Dr. Wade Rinehart, DPT

"Always laugh when you can. It is cheap medicine."

-- Lord Byron

CONFIDENTIALITY NOTICE: This electronic mail transmission may contain information that is confidential, privileged, proprietary, or otherwise legally exempt from disclosure. If you are not the intended recipient, you are hereby notified that you are not authorized to read, print, retain, copy or disseminate this message, any part of it, or any attachments. If you have received this message in error, please delete this message and any attachments from your system without reading the content and notify the sender immediately of the inadvertent transmission. Thank you for your cooperation, HyperbaricsRx.

DISCLAIMER: This email may contain references such as links, articles, abstracts and/or other communications which are provided for general informational purposes only and in no way is intended, nor should be regarded as a substitute for the advice of a licensed physician. Content may reflect professional opinions, however the Food and Drug Administration have not evaluated such statements, if any. Unless specifically cited otherwise, products are not intended to treat, diagnose, cure or prevent any disease.

1 of 2 9/14/2015 5:47 PM

2 of 2 9/14/2015 5:47 PM